Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 449

1.

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.

Rinaldi L, Perrella A, Guarino M, De Luca M, Piai G, Coppola N, Pafundi PC, Ciardiello F, Fasano M, Martinelli E, Valente G, Nevola R, Monari C, Miglioresi L, Guerrera B, Berretta M, Sasso FC, Morisco F, Izzi A, Adinolfi LE.

J Transl Med. 2019 Aug 28;17(1):292. doi: 10.1186/s12967-019-2033-x.

2.

Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.

Petrillo A, Pappalardo A, Pompella L, Tirino G, Calabrese F, Laterza MM, Caterino M, Ventriglia A, Orditura M, Conzo G, Molino C, Ciardiello F, Biglietto M, De Vita F.

Med Oncol. 2019 Aug 23;36(10):83. doi: 10.1007/s12032-019-1306-9.

PMID:
31444639
3.

Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty.

Lordick F, Obermannova R, Vola D, Douillard JY, Mcgregor K, Van Cutsem E, Tabernero J, Ciardiello F, Cervantes A.

ESMO Open. 2019 Jul 5;4(3):e000533. doi: 10.1136/esmoopen-2019-000533. eCollection 2019. Review.

4.

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents.

Rachiglio AM, Lambiase M, Fenizia F, Roma C, Cardone C, Iannaccone A, De Luca A, Carotenuto M, Frezzetti D, Martinelli E, Maiello E, Ciardiello F, Normanno N.

Cancers (Basel). 2019 Jun 20;11(6). pii: E859. doi: 10.3390/cancers11060859.

5.

A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy.

Kumar R, de Vijver MV, Tortora G, Ciardiello F, Goldkorn T, Miller WH Jr, Norton L.

Cancer Res. 2019 Sep 1;79(17):4315-4323. doi: 10.1158/0008-5472.CAN-19-0989. Epub 2019 Jun 18. Review.

PMID:
31213466
6.

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.

Della Corte CM, Barra G, Ciaramella V, Di Liello R, Vicidomini G, Zappavigna S, Luce A, Abate M, Fiorelli A, Caraglia M, Santini M, Martinelli E, Troiani T, Ciardiello F, Morgillo F.

J Exp Clin Cancer Res. 2019 Jun 13;38(1):253. doi: 10.1186/s13046-019-1257-1.

7.

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.

Belli V, Matrone N, Napolitano S, Migliardi G, Cottino F, Bertotti A, Trusolino L, Martinelli E, Morgillo F, Ciardiello D, De Falco V, Giunta EF, Bracale U, Ciardiello F, Troiani T.

J Exp Clin Cancer Res. 2019 Jun 4;38(1):236. doi: 10.1186/s13046-019-1230-z.

8.

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.

De Falco V, Natalicchio MI, Napolitano S, Coppola N, Conzo G, Martinelli E, Zanaletti N, Vitale P, Giunta EF, Vietri MT, Vitiello PP, Ciardiello D, Marinaccio A, De Vita F, Ciardiello F, Troiani T.

Medicine (Baltimore). 2019 May;98(21):e15759. doi: 10.1097/MD.0000000000015759.

9.

Diagnostic value/performance of radiological liver imaging during chemoterapy for gastrointestinal malignancy: a critical review.

Reginelli A, Vacca G, Zanaletti N, Troiani T, Natella R, Maggialetti N, Palumbo P, Giovagnoni A, Ciardiello F, Cappabianca S.

Acta Biomed. 2019 Apr 24;90(5-S):51-61. doi: 10.23750/abm.v90i5-S.8346.

10.

Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy.

Ciardiello D, Vitiello PP, Cardone C, Martini G, Troiani T, Martinelli E, Ciardiello F.

Cancer Treat Rev. 2019 Jun;76:22-32. doi: 10.1016/j.ctrv.2019.04.003. Epub 2019 May 4. Review.

11.

Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from Astragalus boeticus L.

Graziani V, Esposito A, Scognamiglio M, Chambery A, Russo R, Ciardiello F, Troiani T, Potenza N, Fiorentino A, D'Abrosca B.

Molecules. 2019 May 3;24(9). pii: E1725. doi: 10.3390/molecules24091725.

12.

Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients.

Petrillo A, Laterza MM, Tirino G, Pompella L, Pappalardo A, Ventriglia J, Savastano B, Auricchio A, Orditura M, Ciardiello F, Galizia G, De Vita F.

J Gastrointest Oncol. 2019 Apr;10(2):314-323. doi: 10.21037/jgo.2018.12.06.

13.

Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC.

Ciaramella V, Sasso FC, Di Liello R, Corte CMD, Barra G, Viscardi G, Esposito G, Sparano F, Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F.

J Exp Clin Cancer Res. 2019 Apr 26;38(1):178. doi: 10.1186/s13046-019-1176-1.

14.

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators.

Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16. Erratum in: Lancet Oncol. 2019 Jun;20(6):e293.

PMID:
31003911
15.

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.

Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, Bergamo F, Fenocchio E, Martinelli E, Borelli B, Tosi F, Racca P, Valtorta E, Bonoldi E, Martino C, Vaghi C, Marrapese G, Ciardiello F, Zagonel V, Bardelli A, Trusolino L, Torri V, Marsoni S, Siena S.

Oncologist. 2019 Apr 5. pii: theoncologist.2018-0785. doi: 10.1634/theoncologist.2018-0785. [Epub ahead of print]

PMID:
30952821
16.

Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions.

Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, Orditura M, Ciardiello F, Lieto E, Galizia G, Castoro C, De Vita F.

Cancers (Basel). 2019 Mar 21;11(3). pii: E399. doi: 10.3390/cancers11030399. Review.

17.

Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis.

D'Abrosca B, Ciaramella V, Graziani V, Papaccio F, Della Corte CM, Potenza N, Fiorentino A, Ciardiello F, Morgillo F.

Sci Rep. 2019 Mar 21;9(1):4986. doi: 10.1038/s41598-019-41372-1.

18.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.

Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J.

J Clin Oncol. 2019 Jun 10;37(17):1460-1469. doi: 10.1200/JCO.18.02459. Epub 2019 Mar 20.

PMID:
30892987
19.

EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.

Martini G, Cardone C, Vitiello PP, Belli V, Napolitano S, Troiani T, Ciardiello D, Della Corte CM, Morgillo F, Matrone N, Sforza V, Papaccio G, Desiderio V, Paul MC, Moreno-Viedma V, Normanno N, Rachiglio AM, Tirino V, Maiello E, Latiano TP, Rizzi D, Signoriello G, Sibilia M, Ciardiello F, Martinelli E.

Mol Cancer Ther. 2019 Apr;18(4):845-855. doi: 10.1158/1535-7163.MCT-18-0539. Epub 2019 Mar 1.

PMID:
30824612
20.

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.

Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, Barra G, Napolitano S, Della Corte C, Turano M, Furia M, Troiani T, Morgillo F, De Vita F, Ciardiello F, Martinelli E.

J Exp Clin Cancer Res. 2019 Jan 28;38(1):41. doi: 10.1186/s13046-019-1035-0.

21.

PARP inhibitors in ovarian cancer.

Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, De Vita F, Pignata S, Ciardiello F, Orditura M.

Cancer Treat Rev. 2019 Feb;73:1-9. doi: 10.1016/j.ctrv.2018.12.002. Epub 2018 Dec 4. Review.

22.

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy.

Papaccio F, Della Corte CM, Viscardi G, Di Liello R, Esposito G, Sparano F, Ciardiello F, Morgillo F.

Int J Mol Sci. 2018 Nov 14;19(11). pii: E3595. doi: 10.3390/ijms19113595. Review.

23.

What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives.

Tirino G, Pompella L, Petrillo A, Laterza MM, Pappalardo A, Caterino M, Orditura M, Ciardiello F, Galizia G, De Vita F.

Int J Mol Sci. 2018 Sep 7;19(9). pii: E2659. doi: 10.3390/ijms19092659. Review.

24.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC?

Brancaccio G, Napolitano S, Troiani T, Franco R, Iovino F, Reginelli A, Ciardiello F, Argenziano G.

Br J Dermatol. 2018 Dec;179(6):1422-1423. doi: 10.1111/bjd.17145. Epub 2018 Oct 5. No abstract available.

PMID:
30187449
25.

Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety.

Riccardi F, Colantuoni G, Diana A, Mocerino C, Cartenì G, Lauria R, Febbraro A, Nuzzo F, Addeo R, Marano O, Incoronato P, De Placido S, Ciardiello F, Orditura M.

Mol Clin Oncol. 2018 Sep;9(3):255-263. doi: 10.3892/mco.2018.1672. Epub 2018 Jul 16.

26.

Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.

Diana A, Franzese E, Centonze S, Carlino F, Della Corte CM, Ventriglia J, Petrillo A, De Vita F, Alfano R, Ciardiello F, Orditura M.

Curr Oncol Rep. 2018 Aug 20;20(10):76. doi: 10.1007/s11912-018-0726-6. Review.

PMID:
30128845
27.

Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs.

Orditura M, Della Corte CM, Diana A, Ciaramella V, Franzese E, Famiglietti V, Panarese I, Franco R, Grimaldi A, Lombardi A, Caraglia M, Santoriello A, Procaccini E, Lieto E, Maiello E, De Vita F, Ciardiello F, Morgillo F.

Breast. 2018 Oct;41:165-171. doi: 10.1016/j.breast.2018.08.002. Epub 2018 Aug 4.

PMID:
30103105
28.

The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.

Normanno N, Cervantes A, Ciardiello F, De Luca A, Pinto C.

Cancer Treat Rev. 2018 Nov;70:1-8. doi: 10.1016/j.ctrv.2018.07.007. Epub 2018 Jul 18. Review.

PMID:
30053724
29.

Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials.

Gridelli C, Morabito A, Cavanna L, Luciani A, Maione P, Bonanno L, Filipazzi V, Leo S, Cinieri S, Ciardiello F, Burgio MA, Bilancia D, Cortinovis D, Rosetti F, Bianco R, Gebbia V, Artioli F, Bordonaro R, Fregoni V, Mencoboni M, Nelli F, Riccardi F, di Isernia G, Costanzo R, Rocco G, Daniele G, Signoriello S, Piccirillo MC, Gallo C, Perrone F.

J Clin Oncol. 2018 Sep 1;36(25):2585-2592. doi: 10.1200/JCO.2017.76.8390. Epub 2018 Jul 20.

PMID:
30028656
30.

Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.

Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, Sandler A, Yu W, He P, Matheny C, Felizzi F, Rittmeyer A.

Clin Lung Cancer. 2018 Sep;19(5):441-449.e4. doi: 10.1016/j.cllc.2018.05.011. Epub 2018 May 31.

31.

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.

Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limón ML, Saunders M, Sobrero A, Park YS, Ferreiro R, Hong YS, Tomasek J, Taniguchi H, Ciardiello F, Stoehr J, Oum'Hamed Z, Vlassak S, Studeny M, Argiles G.

Ann Oncol. 2018 Sep 1;29(9):1955-1963. doi: 10.1093/annonc/mdy241.

32.

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis.

Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, De Vita F.

Gastroenterol Res Pract. 2018 Jun 10;2018:2373868. doi: 10.1155/2018/2373868. eCollection 2018.

33.

Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy.

Petrillo A, Laterza MM, Tirino G, Pompella L, Ventriglia J, Pappalardo A, Famiglietti V, Martinelli E, Ciardiello F, Orditura M, Galizia G, De Vita F.

Future Oncol. 2018 Oct;14(24):2493-2505. doi: 10.2217/fon-2018-0167. Epub 2018 Jul 3.

PMID:
29969285
34.

It is finally time for adjuvant therapy in melanoma.

Napolitano S, Brancaccio G, Argenziano G, Martinelli E, Morgillo F, Ciardiello F, Troiani T.

Cancer Treat Rev. 2018 Sep;69:101-111. doi: 10.1016/j.ctrv.2018.06.003. Epub 2018 Jun 9. Review.

PMID:
29957365
35.

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?

Roda D, Ciardiello F, Cervantes A.

ESMO Open. 2018 Jun 20;3(4):e000392. doi: 10.1136/esmoopen-2018-000392. eCollection 2018. No abstract available.

36.

30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).

de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, Grossi F, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C.

ESMO Open. 2018 May 31;3(4):e000298. doi: 10.1136/esmoopen-2017-000298. eCollection 2018. Review.

37.

Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota.

Morgillo F, Dallio M, Della Corte CM, Gravina AG, Viscardi G, Loguercio C, Ciardiello F, Federico A.

Neoplasia. 2018 Jul;20(7):721-733. doi: 10.1016/j.neo.2018.05.002. Epub 2018 May 30. Review. No abstract available.

38.

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.

Cremolini C, Rossini D, Martinelli E, Pietrantonio F, Lonardi S, Noventa S, Tamburini E, Frassineti GL, Mosconi S, Nichetti F, Murgioni S, Troiani T, Borelli B, Zucchelli G, Dal Maso A, Sforza V, Masi G, Antoniotti C, Di Bartolomeo M, Miceli R, Ciardiello F, Falcone A.

Oncologist. 2018 Oct;23(10):1178-1187. doi: 10.1634/theoncologist.2017-0573. Epub 2018 May 8.

PMID:
29739893
39.

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells.

Ciaramella V, Della Corte CM, Di Mauro C, Tomassi S, Di Maro S, Troiani T, Martinelli E, Bianco R, Cosconati S, Pierantoni R, Meccariello R, Chianese R, Ciardiello F, Morgillo F.

Oncotarget. 2018 Apr 10;9(27):19273-19282. doi: 10.18632/oncotarget.25018. eCollection 2018 Apr 10.

40.

Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives.

Ciaramella V, Della Corte CM, Ciardiello F, Morgillo F.

Front Endocrinol (Lausanne). 2018 Mar 27;9:115. doi: 10.3389/fendo.2018.00115. eCollection 2018. Review.

41.

Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells.

Graziani V, Scognamiglio M, Belli V, Esposito A, D'Abrosca B, Chambery A, Russo R, Panella M, Russo A, Ciardiello F, Troiani T, Potenza N, Fiorentino A.

Sci Rep. 2018 Mar 28;8(1):5309. doi: 10.1038/s41598-018-23704-9.

42.

Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models.

Della Corte CM, Ciaramella V, Cardone C, La Monica S, Alfieri R, Petronini PG, Malapelle U, Vigliar E, Pepe F, Troncone G, Castellone MD, Troiani T, Martinelli E, Ciardiello F, Morgillo F.

J Thorac Oncol. 2018 Jun;13(6):810-820. doi: 10.1016/j.jtho.2018.02.025. Epub 2018 Mar 8.

43.

Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03).

Pinto C, Di Bisceglie M, Di Fabio F, Bochicchio A, Latiano T, Cordio S, Rosati G, Aschele C, Marino A, Bergamo F, Bustreo S, Frassineti L, Ciardiello F, Damato A, Giaquinta S, Baldari D, Boni L.

Oncologist. 2018 Aug;23(8):912-918. doi: 10.1634/theoncologist.2017-0484. Epub 2018 Mar 9.

44.

Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge.

Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, Farmakis D, López-Fernández T, Lainscak M, Pudil R, Ruschitska F, Seferovic P, Filippatos G, Coats A, Suter T, Von Haehling S, Ciardiello F, de Boer RA, Lyon AR, Tocchetti CG; Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology.

Eur J Heart Fail. 2018 May;20(5):879-887. doi: 10.1002/ejhf.1165. Epub 2018 Feb 21. Review.

45.

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A.

ESMO Open. 2018 Feb 2;3(2):e000285. doi: 10.1136/esmoopen-2017-000285. eCollection 2018.

46.

Role and targeting of anaplastic lymphoma kinase in cancer.

Della Corte CM, Viscardi G, Di Liello R, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F.

Mol Cancer. 2018 Feb 19;17(1):30. doi: 10.1186/s12943-018-0776-2. Review.

47.

Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis.

Reginelli A, Clemente A, Cardone C, Urraro F, Izzo A, Martinelli E, Troiani T, Ciardiello F, Brunese L, Cappabianca S.

Future Oncol. 2018 Dec;14(28):2905-2913. doi: 10.2217/fon-2017-0687. Epub 2018 Feb 13.

PMID:
29433345
48.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J.

JAMA Oncol. 2018 Apr 12;4(4):e175245. doi: 10.1001/jamaoncol.2017.5245. Epub 2018 Apr 12. Erratum in: JAMA Oncol. 2019 May 1;5(5):745.

49.

Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E, Gadgeel S, Papadimitrakopoulou V, Paz-Ares L, Planchard D, Perol M, Hanna N, Sgambato A, Casaluce F, de Marinis F.

Clin Lung Cancer. 2018 Jul;19(4):301-314. doi: 10.1016/j.cllc.2017.12.010. Epub 2017 Dec 22. Review.

PMID:
29396237
50.

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.

Martinelli E, Troiani T, Sforza V, Martini G, Cardone C, Vitiello PP, Ciardiello D, Rachiglio AM, Normanno N, Sartore-Bianchi A, Marsoni S, Bardelli A, Siena S, Ciardiello F.

ESMO Open. 2018 Jan 10;3(1):e000299. doi: 10.1136/esmoopen-2017-000299. eCollection 2018. Erratum in: ESMO Open. 2019 Apr 12;4(2):e000299corr1.

Supplemental Content

Loading ...
Support Center